A council building in Leicestershire has been identified as a mass vaccination site, as the UK prepares to launch large-scale coronavirus strikes if safety regulators give the green light.

The Charnwood Council told Sky News that its office space would be handed over to Defense Department teams by mid-December “for at least nine months”.

Council Chairman Jonathan Morgan said the building would be used as a file Covid-19 A vaccination site “for 185,000 people in the area”.

He said: “We are thrilled to be at the forefront of this, and as soon as the vaccine is ready, this site will be ready to go.”

Charnwood Borough Council Chairman Jonathan Morgan said the site would be used by 185,000 people in the area

The Charnwood Borough Council covers the city of Loughborough, including the university.

This comes as Derby City Council confirmed that talks are underway to use the Derby Arena as a temporary facility to help administer vaccines.

Health Secretary Matt Hancock told Sky News he was hopeful A comprehensive COVID-19 vaccination program will begin ‘in a matter of weeks’.

The vaccine has not yet received official approval, but two US-led treatments have been found to be 90% more effective at protecting people from Corona Virus After the third phase of large-scale experiments.

See also  Duplex apartment in Poznan. Style inspiration from two European cultural poles

The two plants, Pfizer and Moderna, reported overall efficiencies of 95% and 94.5%, respectively.

Please use Chrome Browser for easy-to-access video player

We are “weeks” away from launching the vaccine in the United Kingdom

Pfizer has now said it is asking US regulators to allow emergency use of the vaccine, which it developed with its German partner BioNTech. The UK has requested 40 million doses – enough to treat 20 million people.

Moderna also expects to seek emergency clearance from the United States within weeks. The UK has ordered five million doses of the vaccine by the spring of next year.

Meanwhile, the The COVID-19 vaccine developed by the University of Oxford It produces a strong immune response in the elderly, as data from early trials showed.

Results of Phase 1 and Phase 2 indicate that one of the groups most at risk of death or serious illness from COVID-19 may be able to build immunity, according to data published in The Lancet Medical Journal.

The UK government has ordered over 100 million doses of the Oxford vaccine, and hopes that the final results will prove promising results similar to those of Pfizer and Moderna.